▁Research ▁led ▁the ▁development ▁of ▁the ▁F DA ' s ▁Break through ▁Ther apy ▁design ation , ▁an ▁exped ited ▁review ▁path way ▁for ▁dru gs ▁that ▁show ▁clin ical ▁evidence ▁of ▁superior ity ▁to ▁existing ▁treat ments ▁early ▁in ▁their ▁development . ▁The ▁path way ▁was ▁signed ▁into ▁law ▁on ▁July ▁ 9 , ▁ 2 0 1 2 ▁as ▁part ▁of ▁the ▁Food ▁and ▁D rug ▁Administration ▁Saf ety ▁and ▁In nov ation ▁Act . ▁By ▁January , ▁ 2 0 1 5 , ▁ 7 1 ▁dru gs ▁and ▁bi olog ics ▁had ▁been ▁designated ▁as ▁Break through ▁Ther ap ies ▁and ▁the ▁program ▁had ▁facil itated ▁ 1 8 ▁drug ▁appro val s . ▁ ▁Begin ning ▁in ▁ 2 0 1 2 , ▁Fri ends ▁of ▁Can cer ▁Research ▁organized ▁a ▁series ▁of ▁conference ▁pan els ▁and ▁work sh ops ▁to ▁develop ▁a ▁new ▁clin ical ▁trial ▁structure ▁for ▁target ed ▁squ am ous ▁cell ▁lung ▁cancer ▁dru gs . ▁The ▁resulting ▁trial , ▁L ung - MAP ▁( L ung ▁Can cer ▁Master ▁Pro tocol ), ▁is ▁an ▁" um bre lla ▁trial " ▁that ▁simultaneously ▁tests ▁several ▁different ▁experimental ▁dru gs ▁target ing ▁different ▁gen etic ▁mut ations . ▁The ▁trial ▁is ▁a ▁collaboration ▁among ▁N I H , ▁F DA , ▁SW O G , ▁Foundation ▁Medicine , ▁Fri ends ▁of ▁Can cer ▁Research , ▁and ▁several ▁ph arma ce ut ical ▁companies . ▁L ung - MAP ▁began ▁en rolling ▁patients ▁on ▁June ▁